Yang Michael, Miller Patrick J, Case Brian C, Gilbert Alexander J, Widell Jared K, Rogers Toby, Satler Lowell F, Waksman Ron, Ben-Dor Itsik
MedStar Georgetown University Hospital, Washington, DC, United States of America.
MedStar Heart & Vascular Institute, MedStar Washington Hospital Center, Washington, DC, United States of America.
Cardiovasc Revasc Med. 2019 Jul;20(7):588-593. doi: 10.1016/j.carrev.2019.04.017. Epub 2019 Apr 17.
Cardiovascular disease, a major contributor to morbidity and mortality in chronic kidney disease and kidney transplant patients, is closely evaluated before kidney transplant. We aimed to characterize pre-transplant cardiac testing practices and post-transplant cardiac outcomes at a single academic center.
This was a retrospective, single-center analysis of consecutive adults receiving first renal transplant from 1/1/2016 to 6/31/2017. Data included demographics, medical history, and medications. Pre-transplant workup included echocardiograms, cardiac stress testing, coronary computed tomography, left heart catheterization (LHC), and any revascularization. Outcomes included all-cause mortality, cardiac mortality, myocardial infarction (MI), and myocardial injury.
Our analysis included 235 patients with mean follow-up of 1.6 ± 0.53 years. Of these, 219 (93%) patients had non-invasive functional testing before transplant, with 198 normal and 21 abnormal. The most common modalities were dobutamine stress echocardiogram (88) and pharmacological myocardial perfusion imaging (60). Twenty-four (10%) patients had an LHC, including 14 abnormal studies, and 10 who subsequently underwent successful revascularization. There were 3 deaths, 2 that were cardiac-specific. There were no ST-elevation MIs and 1 Type I non-ST-elevation MI (NSTEMI), occurring 2 days after transplant. Of those patients with a 30-day post-operative troponin, 30 (13%) patients had an elevation due to a type II NSTEMI or myocardial injury.
Non-invasive functional testing is common prior to renal transplantation, with most being normal. Few patients are revascularized before transplantation. Perioperative death and acute coronary syndrome are rare, but troponin elevations due to type II NSTEMI and myocardial injury are common.
心血管疾病是慢性肾脏病和肾移植患者发病和死亡的主要原因,在肾移植前需对其进行密切评估。我们旨在描述一家学术中心的移植前心脏检查实践及移植后心脏结局。
这是一项对2016年1月1日至2017年6月31日接受首次肾移植的连续成年患者进行的回顾性单中心分析。数据包括人口统计学、病史和用药情况。移植前检查包括超声心动图、心脏负荷试验、冠状动脉计算机断层扫描、左心导管检查(LHC)以及任何血运重建术。结局包括全因死亡率、心脏死亡率、心肌梗死(MI)和心肌损伤。
我们的分析纳入了235例患者,平均随访时间为1.6±0.53年。其中,219例(93%)患者在移植前进行了无创功能检查,198例结果正常,21例异常。最常用的检查方式是多巴酚丁胺负荷超声心动图(88例)和药物心肌灌注显像(60例)。24例(10%)患者进行了LHC,其中14例检查结果异常,10例随后成功进行了血运重建术。有3例死亡,其中2例为心脏特异性死亡。无ST段抬高型心肌梗死,有1例1型非ST段抬高型心肌梗死(NSTEMI),发生在移植后2天。在术后30天检测肌钙蛋白的患者中,30例(13%)患者因2型NSTEMI或心肌损伤导致肌钙蛋白升高。
肾移植前无创功能检查很常见,多数结果正常。移植前很少有患者进行血运重建术。围手术期死亡和急性冠状动脉综合征很少见,但2型NSTEMI和心肌损伤导致的肌钙蛋白升高很常见。